Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,782,887 papers from all fields of science
Search
Sign In
Create Free Account
osimertinib
Known as:
Mereletinib
, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Narrower (3)
AZD9291
Tagrisso
osimertinib mesylate
Broader (3)
Antineoplastic Agents
Piperazines
Protein Kinase Inhibitors
Breast Cancer Resistance Protein Inhibitors [MoA]
Kinase Inhibitors [MoA]
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Chemoimmunotherapy combination: Potential option for metastatic NSCLC patients with EGFR mutation resistant to osimertinib.
Bo Yang
,
Yaping Long
,
Y. Hu
Journal of Clinical Oncology
2019
Corpus ID: 190909910
e20618 Background: Osimertinib has been emerged as the standard selection in EGFR T790M-positive NSCLC patients who failed prior…
Expand
2018
2018
First-Line Osimertinib Beneficial in Advanced NSCLC.
Cancer Discovery
2018
Corpus ID: 27242645
Osimertinib is more effective as first-line therapy than other EGFR inhibitors for patients with advanced EGFR-mutated non-small…
Expand
2018
2018
Abstract B03: Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
F. Knebel
,
F. Bettoni
,
+6 authors
A. Camargo
2018
Corpus ID: 91254339
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line…
Expand
Review
2017
Review
2017
1353PCNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17)
C. Zhou
,
Y. Cheng
,
+7 authors
Y.-L. Wu
2017
Corpus ID: 80075542
trials(AURAextension:NCT01802632,AURA2:NCT02094261)inptswithT790M-positiveadvancedNSCLC…
Expand
2017
2017
Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3
R. Pirker
,
A. Buder
,
M. Filipits
2017
Corpus ID: 78444430
Patients with advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) receive first…
Expand
2017
2017
A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
H. Yu
,
S. Hayes
,
+5 authors
M. Kris
2017
Corpus ID: 79566014
9033Background: EGFR tyrosine kinase inhibitors (TKI) are the recommended first line treatment for EGFR-mutant lung cancers…
Expand
2017
2017
Osimertinib – nová volba léčby pro pacienty s mutací EGFR T790M
Martin Svatoň
,
Kristýna Hrdá
,
Milan Pešek
2017
Corpus ID: 79626383
Osimertinib patři mezi 3. generaci tyrozinkinazových inhibitorů (TKI) cilicich na receptor pro epidermalni růstový faktor (EGFR…
Expand
2016
2016
Osimertinib for Patients with
A. Tsao
2016
Corpus ID: 90571306
The T790M epidermal growth factor receptor (EGFR) mutation confers resistance to first- and second-generation EGFR tyrosine…
Expand
2016
2016
Title: Superior efficacy and selectivity of novel small molecule kinase inhibitors of T790M mutant EGFR in preclinical models of lung cancer Running title: EGFR TKIs with improved mutant selectivity…
Yun-Jung Choi
,
Chang-Min Choi
,
+20 authors
Jae Cheol Lee
2016
Corpus ID: 207765276
2016
2016
First-Line Osimertinib Effective in T790m-Mutated EGFR Lung Cancer
P. Goodwin
2016
Corpus ID: 78043264
GENEVA, Switzerland—First-line treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI…
Expand